Merck & Co. Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 Study for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer

Merck & Co. Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 Study for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer

Shots:

  • The P-III KEYNOTE-177 study involves assessing of Keytruda as monothx. vs SOC CT (mFOLFOX6/ FOLFIRI, with/out bevacizumab/ cetuximab) as a 1L treatment in 308 patients with MSI-H or dMMR advanced colorectal cancer
  • The P-III KEYNOTE-177 study resulted in meeting its one of its dual 1EPs i.e. demonstrated significant improvement in PFS. Following the DMC’s recommendation, the study will continue without changes to evaluate OS, the other dual 1EP
  • Keytruda is an anti-PD-1 therapy, act by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 thus activates T lymphocytes affecting both tumor and healthy cells and has received FDA’s approval as the first therapy for use on a biomarker, regardless of tumor type, in prior treated patients with MSI-H or dMMR solid tumors in May’2017

Click here ­to­ read full press release/ article | Ref: Merck & Co. | Image: Lucky Step